Stay updated on AbbVie Press Releases
Sign up to get notified when there's something new on the AbbVie Press Releases page.
Latest updates to the AbbVie Press Releases page
- Check5 days agoChange DetectedRecent updates highlight the advocacy for optimal care for Parkinson's disease patients, including a video featuring a nurse practitioner's insights, while content related to follicular lymphoma treatment options has been removed.SummaryDifference35%
- Check12 days agoChange DetectedAbbVie has made significant announcements, including the acquisition of Nimble Therapeutics to enhance its immunology pipeline and the completion of the acquisition of Aliada Therapeutics, alongside positive clinical trial results for Epcoritamab and Tavapadon.SummaryDifference100%
- Check20 days agoChange DetectedAbbVie is set to present new data on relapsed/refractory multiple myeloma and migraine research focused on women's health at the upcoming Citi's 2024 Global Healthcare Conference and ASH annual meeting, highlighting their commitment to advancing understanding in these areas.SummaryDifference66%
- Check34 days agoChange DetectedRecent updates include AbbVie's European Commission approval of ELAHERE® for treating platinum-resistant ovarian cancer and Allergan Aesthetics offering free online business education courses, while several previous announcements and updates have been removed.SummaryDifference81%
- Check41 days agoChange DetectedAbbVie has recently awarded 20 individuals living with migraine to support their career aspirations and provided an update on the Phase 2 results for Emraclidine in schizophrenia, which did not meet its primary endpoint but was well-tolerated.SummaryDifference59%
- Check48 days agoChange DetectedThe website has added news alerts for email subscribers, highlighted the upcoming BOTOX® Cosmetic Day on November 07, 2024, and announced a partnership to develop novel cancer therapies, while removing recent news about SkinSpirit's support for Girls Inc. and the nationwide availability of JUVÉDERM® VOLUMA® XC.SummaryDifference55%
Stay in the know with updates to AbbVie Press Releases
Enter your email address, and we'll notify you when there's something new on the AbbVie Press Releases page.